18F-FDG PET/CT and extragastric MALT lymphoma: role of Ki-67 score and plasmacytic differentiation

References

• Isaacson P, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer. 1983;50:1410–1416.
   Web of Science ®Google Scholar
• Jaffe ES, Harris NL, Stein H, et al. Tumours of haematopoietic and lymphoid tissues: World health organization classification of tumours, pathology, and genetics. Lyon, France: IARC Press; 2001.
   Google Scholar
• A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin’s lymphoma. The non-Hodgkin’s lymphoma classification project. Blood. 1997;89:3909–3918.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Thieblemont C, Gallamini A, et al. ESMO consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Ann Oncol. 2013;24:857–877.
   PubMed Web of Science ®Google Scholar
• Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of hematological malignancies report of the Clinical Advisory Committee Meeting, Arlie House Virginia, November 1997. Mod Pathol. 2000;13:193–207.
   PubMed Web of Science ®Google Scholar
• Woehrer S, Strubel B, Chott A, et al. Transportation of MALT lymphoma to pure plasma cells histology following treatment with the anti-CD20 antibody rituximab. Leuk Lymphoma. 2005;46:1645–1649.
   PubMed Web of Science ®Google Scholar
• Wohrer S, Troch M, Streubel B, et al. Pathology and clinical course of MALT lymphoma with plasmacytic differentiation. Ann Oncol. 2007;18:2020–2024.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. JCO. 2014;32:3048–3058.
   PubMed Web of Science ®Google Scholar
• Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17:190–197.
   PubMed Web of Science ®Google Scholar
• Cheson BD. Staging and response assessment in lymphomas: the new Lugano classification. Chin Clin Oncol. 2015;4:5.
   PubMed Web of Science ®Google Scholar
• Zucca E, Copie-Bergman C, Ricardi U, et al. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144–vi148.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network guidelines on non-Hodgkin’s lymphomas, version 2.2014. Available from: http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf
   Google Scholar
• Raderer M, Kiesewetter B, Ferreri AJ. Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). Ca Cancer J Clin. 2016;66:152–171.
   Web of Science ®Google Scholar
• Treglia G, Zucca E, Sadeghi R, et al. Detection rate of fluorine-18-fluorodeoxyglucose positron emission tomography in patients with marginal zone lymphoma of MALT type: a meta-analysis. Hematol Oncol. 2015;33:113–124.
   PubMed Web of Science ®Google Scholar
• Albano D, Giubbini R, Bertagna F. 18F-FDG PET/CT and primary hepatic MALT: a case series. Abdom Radiol (NY). 2016;41:1956–1959.
   PubMed Web of Science ®Google Scholar
• Albano D, Bosio G, Orlando E, et al. Role of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in evaluating breast mucosa-associated lymphoid tissue lymphoma: a case series. Hematol Oncol. 2016; DOI: 10.1002/hon.2376
   PubMed Web of Science ®Google Scholar
• Albano D, Bertoli M, Ferro P, et al. 18F-FDG PET/CT in gastric MALT lymphoma: a bicentric experience. Eur J Nucl Med Mol Imaging. 2016; DOI: 10.1007/s00259-016-3518-y
   Web of Science ®Google Scholar
• Hoffmann M, Wöhrer S, Becherer A, et al. 18F-Fluoro-deoxyglucose positron emission tomography in lymphoma of mucosa-associated lymphoid tissue: histology makes the difference. Ann Oncol. 2006;17:1761–1765.
   PubMed Web of Science ®Google Scholar
• Radan L, Fischer D, Bar-Shalom R, et al. FDG avidity and PET/CT patterns in primary gastric lymphoma. Eur J Nucl Med Mol Imaging. 2008;35:1424–1430.
   PubMed Web of Science ®Google Scholar
• Perry C, Herishanu Y, Metzer U, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205–209.
   PubMed Web of Science ®Google Scholar
• Beal KP, Yeung HW, Yahalom J. FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. Ann Oncol. 2005;16:473–480.
   PubMed Web of Science ®Google Scholar
• Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51:25–30.
   PubMed Web of Science ®Google Scholar
• Enomoto K, Hamada K, Inohara H, et al. Mucosa-associated lymphoid tissue lymphoma studied with FDG-PET: a comparison with CT and endoscopic findings. Ann Nucl Med. 2008;22:261–267.
   PubMed Web of Science ®Google Scholar
• Alinari L, Castellucci P, Elstrom R, et al. 18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma. Leuk Lymphoma. 2006;47:2096–2101.
   PubMed Web of Science ®Google Scholar
• Karam M, Novak L, Cyriac J, et al. Role of fluorine-18 fluoro-deoxyglucose positron emission tomography scan in the evaluation and follow-up of patients with low-grade lymphomas. Cancer. 2006;107:175–183.
   PubMed Web of Science ®Google Scholar
• Sharma P, Suman S, Singh H, et al. Primary gastric lymphoma: utility of 18F-fluorodeoxyglucose positron emission tomography-computed tomography for detecting relapse after treatment. Leuk Lymphoma. 2013;54:951–958.
   PubMed Web of Science ®Google Scholar
• Carrillo-Cruz E, Marin-Oyaga V, de la Cruz Vicente F, et al. Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma. Hematol Oncol. 2015;33:151–158.
   PubMed Web of Science ®Google Scholar
• Hwang JW, Jee SR, Lee SH, et al. Efficacy of positron emission tomography/computed tomography in gastric mucosa-associated lymphoid tissue lymphoma. Korean J Gastroenterol. 2016;67:183–188.
   PubMedGoogle Scholar
• Park SH, Lee JJ, Kim HO, et al. 18F-Fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography in mucosa-associated lymphoid tissue lymphoma: variation in 18F-FDG avidity according to site involvement. Leuk Lymphoma. 2015;56:3288–3294.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation- associated human nuclear antigen defined by monoclonal antibody Ki67. J Immunol. 1984;133:1710–1715.
   PubMed Web of Science ®Google Scholar
• Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–873.
   PubMed Web of Science ®Google Scholar
• Gunia S, Kakies C, Erbersdobler A, et al. Scoring the percentage of Ki67 positive nuclei is superior to mitotic count and the mitosis marker phosphohistone H3 (PHH3) in terms of differentiating flat lesions of the bladder mucosa. J Clin Pathol. 2012;65:715–720.
   PubMed Web of Science ®Google Scholar
• Niikura N, Iwamoto T, Masuda S, et al. Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer. Cancer Sci. 2012;103:1508–1512.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Akazawa K, Yao T, et al. A clinicopathologic study of 233 cases with special reference to evaluation with the MIB-1 index. Cancer. 1995;76:1313–1324.
   PubMed Web of Science ®Google Scholar
• Gaudio F, Giordano A, Perrone T, et al. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab. Acta Haematol. 2011;126:44–51.
   PubMed Web of Science ®Google Scholar
• Koo HR, Parl JS, Kang KW, et al. Correlation between (18)F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer. Eur Radiol. 2015;25:3314–3321.
   PubMed Web of Science ®Google Scholar
• Park S, Lee E, Rhee S, et al. Correlation between semi-quantitative (18)F-FDG PET/CT parameters and Ki-67 expression in small cell lung cancer. Nucl Med Mol Imaging. 2016;50:24–30.
   PubMed Web of Science ®Google Scholar
• Du M, Singh N, Hussein A, et al. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoid tissue (MALT). J Pathol. 1996;178:379–384.
   PubMed Web of Science ®Google Scholar
• Stefanaki K, Tzardi M, Kouvidou C, et al. Expression of p53, p21, mdm2, rb, bax and Ki67 proteins in lymphomas of the mucosa-associated lymphoid (MALT) tissue. Anticancer Res. 1998;18:2403–2408.
   PubMed Web of Science ®Google Scholar
• Petit B, Chaury MP, Le Clorennec C, et al. Indolent lymphoplasmacytic and marginal zone B-cell lymphomas: absence of both IRF4 and Ki67 expression identifies a better prognosis subgroup. Haematologica. 2005;90:200–206.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Suefuji H, Hirose Y, et al. 18F-FDG uptake in primary gastric malignant lymphoma correlates with glucose transporter 1 expression and histologic malignant potential. Int J Hematol. 2013;97:43–49.
   PubMed Web of Science ®Google Scholar
• Molina TJ, Lin P, Swerdlow SH, et al. Marginal zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol. 2011;136:211–225.
   PubMed Web of Science ®Google Scholar